Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Intravenous Efgartigimod for the Treatment of Primary Immune Thrombocytopenia in Adults: A Planned, Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study with Open-Label Period (ADVANCE NEXT)

Hanny Al-Samkari, Vickie McDonald, Monica Carpenedo, Francesco Zaja, Nichola Cooper, Spero Cataland, Michael W Drazer, Yoshitaka Miyakawa, Marc Michel, Jaume Ayguasanosa, Janki Brahmbhatt, Lan Lan, Filip Matthijssens, Catherine M. Broome, Waleed Ghanima

Blood (2024) 144 (Supplement 1): 2570.1.

https://doi.org/10.1182/blood-2024-194816

Published: 2024

Journal Articles

Patients with Immune Thrombocytopenia Have Higher Proportion of Ultra Large VWF Multimers and Lower ADAMTS13 Activity Than Healthy Controls

Lamya Garabet, Waleed Ghanima, Åse-Berit Mathisen, Stine Jeanette Lae, Marie Skogstad Le, James B. Bussel, Andreas Hillarp, Carola Henriksson

Blood (2024) 144 (Supplement 1): 2556.

https://doi.org/10.1182/blood-2024-202331

Published: 2024

Journal Articles

Improved Health-Related quality of Life (HRQoL) with Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib Vs Placebo in Adults with Previously Treated Immune Thrombocytopenia (ITP): Phase 3 Luna 3 Multicenter Study

Waleed Ghanima, Howard A. Liebman, Yu Hu, Yoshitaka Miyakawa, Nichola Cooper, Güray Saydam, Marie Luise Hütter-Krönke, Sylvain Audia, Mengjie Yao, Ahmed Daak, Imene Gouia, Matias Cordoba, David J Kuter

Blood (2024) 144 (Supplement 1): 2552.

https://doi.org/10.1182/blood-2024-200279

Published: 2024

Journal Articles

Characterizing Diagnostic Investigations for Suspected Pulmonary Embolism in Postpartum Individuals

Sophie Greutert, Gurjeet Bhangu, Helia Robert-Ebadi, Jeffrey Kline, Marc Righini, Andrea Penaloza, Arnaud Perrier, Waleed Ghanima, Ranjeeta Mallick, Toshihiko Takada, Nick Van Es, Frederikus A Klok, Geert-Jan Geersing, Grégoire Le Gal, Leslie Skeith

Blood (2024) 144 (Supplement 1): 1249.

https://doi.org/10.1182/blood-2024-203216

Published: 2024

Journal Articles

Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)

Blood (2024) 144 (Supplement 1): 5.

https://doi.org/10.1182/blood-2024-199718

Published: 2024

Journal Articles

Ianalumab, a Novel Anti-B-Cell Activating Factor (BAFF) Receptor (BAFF-R) Monoclonal Antibody (mAb) in Development for Immune Thrombocytopenia (ITP) and Warm Autoimmune Hemolytic Anemia (wAIHA), Has Demonstrated a Favorable Safety Profile in Sjögren's Syndrome (SjS), Systemic Lupus Erythematosus (SLE) and Chronic Lymphocytic Leukemia (CLL)

Adam Cuker, Hanny Al-Samkari, Wilma Barcellini, Nichola Cooper, Waleed Ghanima, Marc Michel, Raymond SM Wong, Francesco Zaja, Fengkui Zhang, Patrick Urban, Roberto Abi Rached, David J Kuter

Blood (2023) 142 (Supplement 1): 5427.

https://doi.org/10.1182/blood-2023-180055

Published: 2023

Journal Articles

Patient Experience with Signs, Symptoms, and Daily Impacts of Immune Thrombocytopenia

Waleed Ghanima, Nichola Cooper, Sylvie Bozzi, Ahmed Daak, Imene Gouia, Matias Cordoba, Javier Barrio, Michael Kostikas, Owen Cooper, Howard A. Liebman

Blood (2023) 142 (Supplement 1): 2379.

https://doi.org/10.1182/blood-2023-179124

Published: 2023

Journal Articles

Real-World Use, Effectiveness and Safety of Romiplostim, Eltrombopag and Avatrombopag in Immune Thrombocytopenia: Data from the Norwegian ITP Registry

Riccardo Tomasello, Lamya Garabet, Heidi Pettersen, Eirik Tjønnfjord, Galina Tsykunova, Torkild Pedersen, Hoa Tran, Mariasanta Napolitano, Waleed Ghanima

Blood (2023) 142 (Supplement 1): 3952.

https://doi.org/10.1182/blood-2023-182848

Published: 2023

Journal Articles

Avatrombopag Plus Fostamatinib Combination Efficacy and Safety in Patients with Immune Thrombocytopenia

Maria Eva Mingot Castellano, Begoña Pedrote Amador, Riccardo Tomasello, Waleed Ghanima

Blood (2023) 142 (Supplement 1): 2596.

https://doi.org/10.1182/blood-2023-187518

Published: 2023

Journal Articles

Coagulation in Patients with Immune Thrombocytopenia and Other Associated Autoimmune Disorders

Nora Butta, Elena Monzón Manzano, Paula Acuña, Elena G Arias-Salgado, Maria Isabel Rivas Pollmar, Monica Martin Salces, Ana Mendoza-Martínez, Víctor Jiménez-Yuste, Waleed Ghanima, Maria Teresa Álvarez-Roman

Blood (2023) 142 (Supplement 1): 3962.

https://doi.org/10.1182/blood-2023-188452

Published: 2023

Journal Articles

Validation of Differentially Expressed Micrornas in Primary Immune Thrombocytopenia Suggests Mir-199a-5p Is a Potential Diagnostic Biomarker

Lamya Garabet, Anbjørg Rangberg, Raul Teruel-Montoya, Maria Luisa Lozano, Christine Monceyron Jonassen, Waleed Ghanima

Blood (2023) 142 (Supplement 1): 2579.

https://doi.org/10.1182/blood-2023-184882

Published: 2023

Journal Articles

Interim Baseline Characteristics of Adult Patients with Immune Thrombocytopenia Enrolled in the Observational Multicenter Phase 4 Adopt Study to Evaluate the Use and Effectiveness of Avatrombopag

Waleed Ghanima, Vickie McDonald, Milica Putnik, Brian Jamieson, Stefan Rune Lethagen

Blood (2023) 142 (Supplement 1): 1226.

https://doi.org/10.1182/blood-2023-190106

Published: 2023

Journal Articles

Impact of Age on Hemostasis of Patients with Immune Thrombocytopenia

Elena Monzón Manzano, Maria Teresa Álvarez-Roman, Paula Acuña, Elena G Arias-Salgado, Raquel Ramírez Martín, Maria Cristina Pascual Izquierdo, Maria Isabel Rivas Pollmar, Monica Martin Salces, Waleed Ghanima, Víctor Jiménez-Yuste, Nora Butta

Blood (2023) 142 (Supplement 1): 1211.

https://doi.org/10.1182/blood-2023-185706

Published: 2023

Journal Articles

Health Related Quality of Life in Patients with Primary ITP Compared with Population Norms: A Multicenter Retrospective Analysis of Data from Norwegian ITP Registry

Riccardo Tomasello, Lamya Garabet, Heidi Pettersen, Hoa Tran, Mazdac Tavoly, Galina Tsykunova, Eirik Tjønnfjord, Mariasanta Napolitano, Waleed Ghanima

Blood (2023) 142 (Supplement 1): 3754.

https://doi.org/10.1182/blood-2023-188445

Published: 2023

Journal Articles

The Lack of Tolerable Treatments Options That Can Induce Durable Responses without Fear of Relapse after Discontinuation Represents a Significant Unmet Need for Patients (Pts) with Immune Thrombocytopenia (ITP): Results from the ITP World Impact Survey (I-WISh) 2.0

James B. Bussel, Nichola Cooper, Waleed Ghanima, Drew Provan, Yoshiaki Tomiyama, Ming Hou, Donald Arnold, Cristina Santoro, Francesco Zaja, Barbara Lovrencic, Mervyn Morgan, Leron Lahav, Michal Winograd, Jennifer MacWhirter - DiRaimo, Tom Bailey, Moyra Aziz, Roberto Abi Rached, Caroline Kruse

Blood (2023) 142 (Supplement 1): 1212.

https://doi.org/10.1182/blood-2023-188527

Published: 2023

Journal Articles

A Phase III Clinical Trial Program Investigating the Efficacy and Safety of Ianalumab in Patients with Primary Immune Thrombocytopenia (VAYHIT1 and VAYHIT2) and Warm Autoimmune Hemolytic Anemia (VAYHIA)

Hanny Al-Samkari, Wilma Barcellini, Nichola Cooper, Waleed Ghanima, Marc Michel, Raymond SM Wong, Francesco Zaja, Fengkui Zhang, Patrick Urban, Alex Allepuz, Justyna Fronczek-Sokol, Jens Haenig, Pascal Edrich, Adam Cuker

Blood (2023) 142 (Supplement 1): 5456.

https://doi.org/10.1182/blood-2023-180647

Published: 2023

Journal Articles

Clinical Predictors of Response to Rilzabrutinib Therapy in Patients with Immune Thrombocytopenia: Exploratory Analysis of a Phase 1/2 Study

David J. Kuter, Waleed Ghanima, Umer Khan, Mengyao Li, Jenny Shan, Ahmed Daak, Nichola Cooper

Blood (2022) 140 (Supplement 1): 5559–5561.

https://doi.org/10.1182/blood-2022-162426

Published: 2022

Journal Articles

Bleedings in Cancer Patients Treated with Apixaban for Venous Thromboembolism

Parwana Hussaini, Trine-Lise Larsen, Waleed Ghanima, Anders Erik Astrup Dahm

Blood (2022) 140 (Supplement 1): 5682–5683.

https://doi.org/10.1182/blood-2022-164857

Published: 2022

Journal Articles

Updated Phase I/II Safety and Efficacy Results for Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed/Refractory Immune Thrombocytopenia

Blood (2021) 138 (Supplement 1): 14.

https://doi.org/10.1182/blood-2021-145128

Published: 2021

Journal Articles

LUNA3 Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of the Oral BTK Inhibitor Rilzabrutinib in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia

David J. Kuter, James B Bussel, Nichola Cooper, Terry Gernsheimer, Michele P. Lambert, Howard Liebman, Michael D Tarantino, Olga Bandman, Puneet Arora, Ann Neale, Regan Burns, Mengjie Yao, Waleed Ghanima

Blood (2021) 138 (Supplement 1): 1010.

https://doi.org/10.1182/blood-2021-144504

Published: 2021

NARROW

Intravenous Efgartigimod for the Treatment of Primary Immune Thrombocytopenia in Adults: A Planned, Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study with Open-Label Period (ADVANCE NEXT)

Patients with Immune Thrombocytopenia Have Higher Proportion of Ultra Large VWF Multimers and Lower ADAMTS13 Activity Than Healthy Controls

Improved Health-Related quality of Life (HRQoL) with Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib Vs Placebo in Adults with Previously Treated Immune Thrombocytopenia (ITP): Phase 3 Luna 3 Multicenter Study

Characterizing Diagnostic Investigations for Suspected Pulmonary Embolism in Postpartum Individuals

Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)

Patient Experience with Signs, Symptoms, and Daily Impacts of Immune Thrombocytopenia

Real-World Use, Effectiveness and Safety of Romiplostim, Eltrombopag and Avatrombopag in Immune Thrombocytopenia: Data from the Norwegian ITP Registry

Avatrombopag Plus Fostamatinib Combination Efficacy and Safety in Patients with Immune Thrombocytopenia

Coagulation in Patients with Immune Thrombocytopenia and Other Associated Autoimmune Disorders

Validation of Differentially Expressed Micrornas in Primary Immune Thrombocytopenia Suggests Mir-199a-5p Is a Potential Diagnostic Biomarker

Interim Baseline Characteristics of Adult Patients with Immune Thrombocytopenia Enrolled in the Observational Multicenter Phase 4 Adopt Study to Evaluate the Use and Effectiveness of Avatrombopag

Impact of Age on Hemostasis of Patients with Immune Thrombocytopenia

Health Related Quality of Life in Patients with Primary ITP Compared with Population Norms: A Multicenter Retrospective Analysis of Data from Norwegian ITP Registry

The Lack of Tolerable Treatments Options That Can Induce Durable Responses without Fear of Relapse after Discontinuation Represents a Significant Unmet Need for Patients (Pts) with Immune Thrombocytopenia (ITP): Results from the ITP World Impact Survey (I-WISh) 2.0

A Phase III Clinical Trial Program Investigating the Efficacy and Safety of Ianalumab in Patients with Primary Immune Thrombocytopenia (VAYHIT1 and VAYHIT2) and Warm Autoimmune Hemolytic Anemia (VAYHIA)

Clinical Predictors of Response to Rilzabrutinib Therapy in Patients with Immune Thrombocytopenia: Exploratory Analysis of a Phase 1/2 Study

Bleedings in Cancer Patients Treated with Apixaban for Venous Thromboembolism

Updated Phase I/II Safety and Efficacy Results for Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed/Refractory Immune Thrombocytopenia

LUNA3 Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of the Oral BTK Inhibitor Rilzabrutinib in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only